Sequential B-Cell Epitopes ofBacillus anthracisLethal Factor Bind Lethal Toxin-Neutralizing Antibodies
- 1 January 2009
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 77 (1), 162-169
- https://doi.org/10.1128/iai.00788-08
Abstract
The bipartite anthrax lethal toxin (LeTx) consisting of protective antigen (PA) and lethal factor (LF) is a major virulence factor contributing to death from systemicBacillus anthracisinfection. The current vaccine elicits antibodies directed primarily to PA; however, in experimental settings serologic responses to LF can neutralize LeTx and contribute to protection against infection. The goals of the present study were to identify sequential B-cell epitopes of LF and to determine the capacity of these determinants to bind neutralizing antibodies. Sera of recombinant LF-immunized A/J mice exhibited high titers of immunoglobulin G anti-LF reactivity that neutralized LeTx in vitro 78 days after the final booster immunization and protected the mice from in vivo challenge with 3 50% lethal doses of LeTx. These sera bound multiple discontinuous epitopes, and there were major clusters of reactivity on native LF. Strikingly, all three neutralizing, LF-specific monoclonal antibodies tested bound specific peptide sequences that coincided with sequential epitopes identified in polyclonal antisera from recombinant LF-immunized mice. This study confirms that LF induces high-titer protective antibodies in vitro and in vivo. Moreover, the binding of short LF peptides by LF-specific neutralizing monoclonal antibodies suggests that generation of protective antibodies by peptide vaccination may be feasible for this antigen. This study paves the way for a more effective anthrax vaccine by identifying discontinuous peptide epitopes of LF.Keywords
This publication has 54 references indexed in Scilit:
- Detoxified Lethal Toxin as a Potential Mucosal Vaccine against AnthraxClinical and Vaccine Immunology, 2008
- Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect againstBacillus anthracisInfection and Enhance Endogenous Immunity to AnthraxInfection and Immunity, 2007
- In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of ImmunityInfection and Immunity, 2007
- High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex FormationAntimicrobial Agents and Chemotherapy, 2007
- Anthrax Lethal Toxin-Mediated Killing of Human and Murine Dendritic Cells Impairs the Adaptive Immune ResponsePLoS Pathogens, 2005
- Bacillus anthracis, a story of nature subverted by manLetters in Applied Microbiology, 2005
- Immunogenicity of Well-Characterized SyntheticPlasmodium falciparumMultiple Antigen Peptide ConjugatesInfection and Immunity, 2001
- The Protein Data BankNucleic Acids Research, 2000
- AnthraxThe New England Journal of Medicine, 1999
- Anthrax Lethal Factor Cleaves the N-Terminus of MAPKKs and Induces Tyrosine/Threonine Phosphorylation of MAPKs in Cultured MacrophagesBiochemical and Biophysical Research Communications, 1998